Reversibility of regorafenib effects in hepatocellular carcinoma cells

瑞戈非尼对肝细胞癌细胞作用的可逆性

阅读:8
作者:Rosalba D'Alessandro, Maria G Refolo, Catia Lippolis, Caterina Messa, Aldo Cavallini, Roberta Rossi, Leonardo Resta, Antonio Di Carlo, Brian I Carr

Conclusions

Removal of regorafenib from growth-inhibited cells resulted in a JNK-dependent recovery of growth and migration.

Methods

Cell proliferation, motility, and invasion were analyzed by MTT, wound healing, and invasion assays, respectively, and MAPK pathway protein markers were analyzed by Western blot.

Purpose

Multikinase growth inhibitors inhibit their target kinases with varying potency. Patients often require lower doses or therapy breaks due to drug toxicities. To evaluate the effects of drug withdrawal on hepatocellular carcinoma cells after incubation with growth-inhibitory concentrations of regorafenib, cell growth, migration and invasion, and signaling were examined.

Results

After regorafenib removal, cell growth, migration, and invasion recovered. Repeated drug exposure resulted in changes in cell growth patterns. Recovery could be blocked by sub-growth-inhibitory concentrations of either doxorubicin or vitamin K1. Recovery of growth was associated with increased phospho-JNK, phospho-p38, and phospho-STAT3 levels. The recovery of growth, migration, and signaling were blocked by a JNK inhibitor. Conclusions: Removal of regorafenib from growth-inhibited cells resulted in a JNK-dependent recovery of growth and migration.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。